KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OSПодробнее

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS

Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)Подробнее

Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBCПодробнее

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC

GS1-01: "Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant..."Подробнее

GS1-01: 'Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant...'

Special Session: "Regulatory Insights to the 2021 Early Stage Breast Cancer Approvals..."Подробнее

Special Session: 'Regulatory Insights to the 2021 Early Stage Breast Cancer Approvals...'